CF
FULC icon

Cantor Fitzgerald’s Fulcrum Therapeutics FULC Stock Holding History

Cantor Fitzgerald’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$94K – 348
2024
Q4 		$94K Buy
+20,000
New +$73.8K ﹤0.01% 212

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cantor Fitzgerald's FULC Position: Q1 2025 in Review

Cantor Fitzgerald sold out of Fulcrum Therapeutics (FULC) in Q1 2025, closing a stake of 20,000 shares — an estimated $94K sold.

Cantor Fitzgerald first reported a position in FULC in Q4 2024 and held it in 1 quarter. The position peaked at $94K in Q4 2024. 117 funds tracked by Wall St. Rank hold FULC as of Q1 2025.

  • Cantor Fitzgerald reported no remaining Fulcrum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 20,000 Fulcrum Therapeutics shares in Q1 2025, an estimated $94K.
  • Cantor Fitzgerald first reported a position in Fulcrum Therapeutics in Q4 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's Fulcrum Therapeutics position peaked at $94K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2025.

Based on Cantor Fitzgerald's 13F filing for Q1 2025, filed 15 May 2025.